NasdaqGS:COGTBiotechs
Is 48-Week Bezuclastinib Data in Systemic Mastocytosis Altering The Investment Case For Cogent Biosciences (COGT)?
Cogent Biosciences recently reported additional clinical results from its pivotal SUMMIT trial of bezuclastinib in NonAdvanced Systemic Mastocytosis, showing rapid, durable and statistically significant improvements in symptoms, disease biomarkers and bone mineral density over 48 weeks.
The new data also suggest potential disease modification and meaningful benefit for patients with high unmet need, reinforcing bezuclastinib’s clinical relevance in this rare mast cell disorder.
We’ll now...